JP2025102836A5 - - Google Patents

Info

Publication number
JP2025102836A5
JP2025102836A5 JP2025047199A JP2025047199A JP2025102836A5 JP 2025102836 A5 JP2025102836 A5 JP 2025102836A5 JP 2025047199 A JP2025047199 A JP 2025047199A JP 2025047199 A JP2025047199 A JP 2025047199A JP 2025102836 A5 JP2025102836 A5 JP 2025102836A5
Authority
JP
Japan
Prior art keywords
bispecific antibody
cancer
pharmaceutical composition
conjugate
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025047199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025102836A (ja
Filing date
Publication date
Priority claimed from JP2022506483A external-priority patent/JP7655896B2/ja
Application filed filed Critical
Publication of JP2025102836A publication Critical patent/JP2025102836A/ja
Publication of JP2025102836A5 publication Critical patent/JP2025102836A5/ja
Pending legal-status Critical Current

Links

JP2025047199A 2019-08-02 2025-03-21 抗ctla4/抗pd-1二重特異性抗体及びその使用 Pending JP2025102836A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201910711122.4 2019-08-02
CN201910711122 2019-08-02
CN201911224135.5 2019-12-02
CN201911224135 2019-12-02
JP2022506483A JP7655896B2 (ja) 2019-08-02 2020-07-31 抗ctla4/抗pd-1二重特異性抗体及びその使用
PCT/CN2020/106309 WO2021023117A1 (zh) 2019-08-02 2020-07-31 抗ctla4-抗pd-1双特异性抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022506483A Division JP7655896B2 (ja) 2019-08-02 2020-07-31 抗ctla4/抗pd-1二重特異性抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2025102836A JP2025102836A (ja) 2025-07-08
JP2025102836A5 true JP2025102836A5 (cg-RX-API-DMAC7.html) 2025-10-30

Family

ID=74483591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506483A Active JP7655896B2 (ja) 2019-08-02 2020-07-31 抗ctla4/抗pd-1二重特異性抗体及びその使用
JP2025047199A Pending JP2025102836A (ja) 2019-08-02 2025-03-21 抗ctla4/抗pd-1二重特異性抗体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022506483A Active JP7655896B2 (ja) 2019-08-02 2020-07-31 抗ctla4/抗pd-1二重特異性抗体及びその使用

Country Status (12)

Country Link
US (1) US20220275089A1 (cg-RX-API-DMAC7.html)
EP (1) EP4008730A4 (cg-RX-API-DMAC7.html)
JP (2) JP7655896B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220053578A (cg-RX-API-DMAC7.html)
CN (2) CN122502501A (cg-RX-API-DMAC7.html)
AU (1) AU2020325350A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022002013A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146780A1 (cg-RX-API-DMAC7.html)
IL (2) IL321822A (cg-RX-API-DMAC7.html)
MX (1) MX2022001321A (cg-RX-API-DMAC7.html)
PH (1) PH12022550243A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021023117A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
JP2023515675A (ja) * 2020-03-05 2023-04-13 メルク・シャープ・アンド・ドーム・エルエルシー Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
CN118530342A (zh) * 2021-03-12 2024-08-23 中山康方生物医药有限公司 降低免疫细胞分泌il-8和/或il-6的水平的方法
AU2022233411A1 (en) * 2021-03-12 2023-09-14 Akeso Biopharma, Inc. Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
WO2022218384A1 (zh) * 2021-04-14 2022-10-20 中山康方生物医药有限公司 抗cd47的单克隆抗体及其用途
IL307494A (en) * 2021-04-14 2023-12-01 Akeso Pharmaceuticals Inc Use of antibody in anti-tumor treatment
US20240352153A1 (en) * 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
KR20240153590A (ko) * 2022-02-24 2024-10-23 아케소 파마슈티컬스, 인코포레이티드 항-ctla4-항-pd-1 이중특이적 항체 및 치아우라닙을 포함하는 약제학적 조성물
IL315307A (en) * 2022-03-07 2024-10-01 Medimmune Llc Treatment methods using CTLA-4 and PD-1 bispecific antibodies
CN118946366A (zh) * 2022-04-13 2024-11-12 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
US20240117051A1 (en) 2022-09-09 2024-04-11 Akeso Biopharma, Inc. Therapeutic combination and use thereof
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof
CN118272524A (zh) * 2022-12-30 2024-07-02 康方药业有限公司 Cd74的医药用途
EP4678186A1 (en) * 2023-03-07 2026-01-14 Akeso Pharma Co., Ltd. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof
WO2024199435A1 (zh) * 2023-03-31 2024-10-03 上海细胞治疗集团股份有限公司 双特异性抗体及自分泌双特异性抗体的工程化免疫细胞
CN118767127A (zh) * 2023-04-10 2024-10-15 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体的医药用途
CN120361206A (zh) * 2024-01-25 2025-07-25 中山康方生物医药有限公司 抗pd-1-抗vegfa的双特异性抗体的医药用途
WO2025201450A1 (zh) * 2024-03-27 2025-10-02 康方汇科(上海)生物有限公司 药物组合及用途
WO2025232896A1 (zh) * 2024-05-10 2025-11-13 康方汇科(上海)生物有限公司 药物组合及用途
CN120965861B (zh) * 2025-10-22 2026-02-13 杭州博茵生物技术有限公司 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
EA201500417A1 (ru) * 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
CN102711810B (zh) * 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
IL290457B2 (en) * 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
RU2693661C2 (ru) 2016-03-04 2019-07-03 Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. Антитело против pdl-1, его фармацевтическая композиция и применение
EP3493845A4 (en) * 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN110325549B (zh) * 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
CN106699891B (zh) * 2017-01-25 2019-04-09 北京天广实生物技术股份有限公司 一种抗pd-l1抗体、其药物组合物及其用途
US20200199247A1 (en) * 2017-06-07 2020-06-25 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆(苏州)医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES

Similar Documents

Publication Publication Date Title
IL293241A (en) Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
JP2023504003A5 (cg-RX-API-DMAC7.html)
JP2022542450A5 (cg-RX-API-DMAC7.html)
JP7655896B2 (ja) 抗ctla4/抗pd-1二重特異性抗体及びその使用
Li et al. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
JP2023022036A5 (cg-RX-API-DMAC7.html)
JP2021525082A5 (cg-RX-API-DMAC7.html)
Bakema et al. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer
JP2020500540A5 (cg-RX-API-DMAC7.html)
TWI593707B (zh) Cd33抗體類及彼等於治療癌症之用途
JP2024509018A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
EP3864045A2 (en) Dll3 single domain antibodies and therapeutic compositions thereof
JP2021526512A5 (cg-RX-API-DMAC7.html)
IL258202B2 (en) CD3-binding polypeptides, a method for their preparation, pharmaceutical preparations, nucleic acids, vectors and the use of such polypeptides
AU2019356573A1 (en) PD-1 single domain antibodies and therapeutic compositions thereof
JP2024515396A5 (cg-RX-API-DMAC7.html)
JP2021531764A5 (cg-RX-API-DMAC7.html)
CA3114693A1 (en) 5t4 single domain antibodies and therapeutic compositions thereof
JP2022507485A (ja) Cd38抗体とicam1抗体およびそれらの使用
JP2023522730A5 (cg-RX-API-DMAC7.html)
JP2024515618A5 (cg-RX-API-DMAC7.html)
CN115197325A (zh) 抗体在抗肿瘤治疗中的用途
Du et al. Engineered bifunctional proteins for targeted cancer therapy: prospects and challenges
JP2025504496A5 (cg-RX-API-DMAC7.html)